Closely-held ArcherDX acquired genetic testing lab, Baby Genes. It will operate as a wholly-owned subsidiary under the name ArcherDX Clinical Services, and continue to market a suite of existing newborn genetic testing and carrier screening services under the Baby Genes brand name.
Baby Genes is a CLIA-certified and College of American Pathologists-accredited (CAP) genetics lab in Golden, Colorado. It‘s test menu includes a supplemental newborn screening panel of more than 100 genes, covering more than 72 clinically actionable, inherited conditions.
It also offers predefined carrier screening tests that include full-gene sequencing for cystic fibrosis, spinal muscular atrophy and Fragile X syndrome, as well as customized confirmatory and reflex genetic testing services to physicians.
“We have a long, positive working relationship with Baby Genes and from day one, we saw natural alignment between the two organizations regarding our shared commitment to accelerating the adoption and application of personalized health,” Jason Myers, co-founder and CEO of ArcherDX, said in a statement.
“The addition of a CLIA/CAP-accredited lab enables our mission, not through centralizing testing, [but by allowing] us to extend our capabilities in the genetic testing market, improve our ability to understand and anticipate our customers’ needs – especially those customers looking to implement next-generating sequencing (NGS) for the first time or expand NGS capabilities, and to enhance our biopharma partner co-development capabilities,” he added.
Richard Sjogren, the co-founder and CEO of Baby Genes, will join ArcherDX’s senior management team as VP of operations.
